H Hassoun

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma
    Hani Hassoun
    Division of Hematologic Oncology, Department of Medicine, Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 132:155-61. 2006
  2. doi request reprint High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease
    H Hassoun
    Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Bone Marrow Transplant 42:405-12. 2008
  3. ncbi request reprint Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation
    R L Comenzo
    Hematology Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Leukemia 20:345-9. 2006
  4. doi request reprint Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis
    H Landau
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leukemia 27:823-8. 2013
  5. doi request reprint Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center
    M Pozotrigo
    Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Bone Marrow Transplant 48:1033-9. 2013
  6. doi request reprint Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone
    D Lebovic
    Department of Medicine, Weill Cornell School of Medicine, New York Hospital, NY, USA
    Br J Haematol 143:369-73. 2008
  7. pmc Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis
    H Landau
    Department of Medicine, New York Presbyterian Hospital Weill Cornell Medical College, New York, NY, USA
    Leukemia . 2016
  8. ncbi request reprint Adjuvant bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in patients with light-chain amyloidosis (AL)
    H J Landau
    Memorial Sloan Kettering Cancer Center, New York, NY Fox Chase Cancer Center, Philadelphia, PA Tufts Medical Center, Boston, MA
    J Clin Oncol 27:8540. 2009
  9. ncbi request reprint FDG PET/CT (FDG PET) in evaluation of response in patients with multiple myeloma (MM) treated with bortezomib, pegylated liposomal doxorubicin, and dexamethasone
    N Pandit-Taskar
    Memorial Sloan Kettering Cancer Center, New York, NY Tufts Medical Center, Boston, MA Fox Chase Cancer Center, Philadelphia, PA
    J Clin Oncol 27:8533. 2009
  10. ncbi request reprint Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial
    S Gupta
    Hematology Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Bone Marrow Transplant 35:441-7. 2005

Collaborators

Detail Information

Publications18

  1. ncbi request reprint Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma
    Hani Hassoun
    Division of Hematologic Oncology, Department of Medicine, Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 132:155-61. 2006
    ..AD-TD administered with low dose aspirin for deep vein thrombosis prophylaxis was well tolerated and yielded a high response rate with minimal treatment-related morbidity...
  2. doi request reprint High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease
    H Hassoun
    Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Bone Marrow Transplant 42:405-12. 2008
    ..Although this approach appears effective, multi-center studies are needed to define the optimal treatment for patients with MIDD...
  3. ncbi request reprint Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation
    R L Comenzo
    Hematology Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Leukemia 20:345-9. 2006
    ..PFS for those with CR or nCR was 3.1 years while for those with stable disease (SD) it was 1.3 years (P=0.06). We conclude that carmustine can be combined with HDM for myeloma with minimal pulmonary toxicity and a high response rate...
  4. doi request reprint Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis
    H Landau
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leukemia 27:823-8. 2013
    ..One patient with serologic progression had organ impairment at time of progression. In newly diagnosed AL, BD following SCT rapidly and effectively improves responses resulting in high CR rates and maintained organ improvement...
  5. doi request reprint Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center
    M Pozotrigo
    Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Bone Marrow Transplant 48:1033-9. 2013
    ..The data support the current International Multiple Myeloma Working Group guidelines recommending the use of cyclophosphamide and G-CSF based mobilization for patients previously exposed to lenalidomide. ..
  6. doi request reprint Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone
    D Lebovic
    Department of Medicine, Weill Cornell School of Medicine, New York Hospital, NY, USA
    Br J Haematol 143:369-73. 2008
    ..The haematological response rate was 58% (23/40) with 13% (5/40) complete responses; most responses were noted in <3 cycles. Achievement of a rapid response to therapy extends survival...
  7. pmc Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis
    H Landau
    Department of Medicine, New York Presbyterian Hospital Weill Cornell Medical College, New York, NY, USA
    Leukemia . 2016
    ..With the availability of novel agents for consolidation, RA-SCT remains a very effective and important backbone treatment for AL amyloidosis.Leukemia advance online publication, 30 September 2016; doi:10.1038/leu.2016.229...
  8. ncbi request reprint Adjuvant bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in patients with light-chain amyloidosis (AL)
    H J Landau
    Memorial Sloan Kettering Cancer Center, New York, NY Fox Chase Cancer Center, Philadelphia, PA Tufts Medical Center, Boston, MA
    J Clin Oncol 27:8540. 2009
    ..In this phase II trial we use bortezomib (Bort) in place of Thal in an effort to further improve frequency and depth of response...
  9. ncbi request reprint FDG PET/CT (FDG PET) in evaluation of response in patients with multiple myeloma (MM) treated with bortezomib, pegylated liposomal doxorubicin, and dexamethasone
    N Pandit-Taskar
    Memorial Sloan Kettering Cancer Center, New York, NY Tufts Medical Center, Boston, MA Fox Chase Cancer Center, Philadelphia, PA
    J Clin Oncol 27:8533. 2009
    ..8533 Background: In a high risk population of pts with newly diagnosed or primary refractory MM, we prospectively studied FDG PET imaging to determine the value of PET/CT in assessing therapeutic response...
  10. ncbi request reprint Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial
    S Gupta
    Hematology Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Bone Marrow Transplant 35:441-7. 2005
    ..2). Increased contamination was associated with increased patient age. This strategy for mobilization is feasible, frequently requires hospitalization and transfusion, and controls disease in most patients...
  11. pmc Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients' monitoring after transplantation
    D Zamarin
    Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Bone Marrow Transplant 48:419-24. 2013
    ..Our findings provide important evidence-based recommendations that strengthen current monitoring guidelines after first-line ASCT in MM...
  12. doi request reprint Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study
    S Afifi
    Pharmacy Department, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Bone Marrow Transplant 51:546-52. 2016
    ..001) as well as using Medicare reimbursement rates (P=0.27). Higher rate of hospitalization, increased need for salvage mobilization, and increased G-CSF use account for these differences. ..
  13. ncbi request reprint Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma
    D R Feldman
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 26:5100. 2008
    ..The safety and maximum tolerated dose (MTD) of sunitinib in combination with bevacizumab was assessed in this Phase I trial...
  14. pmc A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma
    T E Witzig
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN, USA
    Leukemia 27:220-5. 2013
    ..The addition of Thal to standard ZLD produces anti-tumor responses whereas ZLD alone does not. Thal/ZLD also prolongs TTP from AMM to MM. This study provides the rationale for further studies in patients with AMM to delay chemotherapy...
  15. doi request reprint High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis
    Russell A Moore
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room H709, New York, NY 10065, USA
    J Clin Oncol 29:3466-73. 2011
    ....
  16. ncbi request reprint Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial
    Adam D Cohen
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 139:224-33. 2007
    ..Risk-adapted SCT with adjuvant thal/dex is feasible and results in low TRM and high haematological and organ response rates in AL patients...
  17. pmc Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications
    David H Chang
    Laboratory of Tumor Immunology and Immunotherapy, The Rockefeller University, New York, NY 10021, USA
    Blood 108:618-21. 2006
    ..Together these data demonstrate that LEN and its analogues enhance CD1d-mediated presentation of glycolipid antigens and support combining these agents with NKT targeted approaches for protection against tumors...
  18. ncbi request reprint Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease
    Madhav V Dhodapkar
    Laboratory of Tumor Immunology and Immunotherapy, The Rockefeller University, New York, NY 10021, USA
    Cancer Immun 3:9. 2003
    ..These data suggest that CT antigens may have important biological implications in malignant gammopathies and that CT-7 may be a suitable target for T cell-based and possibly antibody-mediated immunotherapy of myeloma...